The study aims to test the safety and effectiveness of a medicine called retatrutide for people with Type 2 Diabetes (T2D) and who are also overweight or obese. It lasts about 89 weeks and involves up to 24 visits to the study site. Some participants may also have a condition called obstructive sleep apnea (OSA), a sleep disorder where breathing stops and starts repeatedly.
Eligibility: To join, you need a Body Mass Index (BMI) of 27 or higher, which measures body fat based on weight and height. You should have Type 2 Diabetes and be on stable diabetes treatment for at least 90 days. You should have tried but not succeeded in losing weight through diet.
- Study Length: 89 weeks, with up to 24 visits.
- Compensation: Participants may receive compensation, but details are not specified.
- Risks and Treatments: May involve stopping OSA therapy temporarily for sleep studies, and careful monitoring for safety.
Before joining, ensure you don’t have significant recent weight changes, haven't taken weight loss drugs recently, or had planned surgery for obesity. Make sure to discuss with your doctor if this study is right for you.